scarring | GenomeWeb

scarring

The drug is designed to silence connective tissue growth factor, which is implicated in scarring and fibrosis.

RXi Pharmaceuticals said this week that it has signed a deal giving the European Union distribution rights to its investigational anti-scarring drug RXI-109 to UK-based Ethicor.

This article has been updated to include details about RXi's third quarter financial results.
RXi Pharmaceuticals this week announced that it has begun dosing patients in a phase II trial of its investigational anti-scarring drug RXI-109.

RXi Pharmaceuticals this week released data from a phase I trial of its dermal anti-scarring drug RXI-109, showing that the compound was safe and well-tolerated.

RXi Pharmaceuticals this week announced that its lead drug candidate, the anti-scarring agent RXI-109, was safe and well tolerated in a phase I study, while producing a dose-dependent reduction of its target protein.

Having just raised $16 million through the sale of around 113 million shares, RXi Pharmaceuticals last week said that it now has the financial means to funds its operations, including the phase II development of its lead RNAi drug candidate, into 2015.

RXi Pharmaceuticals has completed patient dosing in the second of two phase I trials of its lead drug candidate, the anti-scarring agent RXI-109, and is on track to initiating a phase II study before the end of the year, the company's top executive said last week.

RXi Pharmaceuticals this week announced that it has started a second double-blind phase I study of its RNAi-based anti-scarring compound RXI-109.

RXi Pharmaceuticals this week announced the pharmacokinetic results of a single dose phase I trial of its intradermal anti-scarring drug RXI-109.

RXi Pharmaceuticals this week announced that it has completed patient dosing in a phase I trial of its first clinical candidate, the RNAi-based dermal scarring drug RXI-109.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.